Our findings are consistent with a recent meta-analysis showing that metformin and GLP-1 receptor agonists (GLP-1 RAs) can improve insulin sensitivity, reduce testosterone levels, and mitigate the risk of cardiovascular disease in women with PCOS [43]. Here, GLP1R is linked to polycystic ovary syndrome.